Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
|Articles|December 23, 2021
Daily OTC Pearl: Live Better Tea Tree Oil
Author(s)Saro Arakelians, PharmD
Tea tree oil is indicated for everyday use associated with its cleansing properties.
Advertisement
OTC/Lifestyle Pearl of the Day: Live Better Tea Tree Oil
Indication: Live Better Tea Tree Oil is made from organic tea tree oil and is indicated for everyday use associated with its cleansing properties, such as to freshen or cleanse the environment, skin, hair, fingernails, or toenails.
Insight:
- This product is certified organic by the USDA and is a 100% pure, vegan, and GC-MS tested product.
- Ingredients in Live Better Tea Tree Oil include organic melaleuca alternifolia (tea tree) leaf oil.
- Directions for use: A few drops of Live Better Tea Tree Oil can be added to an essential oil diffuser or spray mister for use. For bath or body application, the oil should be diluted to 3%.
- Live Better Tea Tree Oil should be stored in a cool, dark place.
- Live Better Tea Tree Oil should be used within 2 to 3 years after opening.
- Cautions: Live Better Tea Tree Oil is not for internal use. The oil should not come in contact with the eyes or mucous membranes. The oil should not be used for children under 6 years of age.
- Adverse events (AEs): The most common AE associated with the use of Live Better Tea Tree Oil is irritated skin, which is frequently caused from the oil being applied to the skin without dilution. If skin irritation occurs, use of the oil should be discontinued.
Source:
Advertisement
Related to this article
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
3
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
4
Safety and Monitoring – Hypophosphatemia, Infusion Reactions, and Adverse-Event Management
5